nodes	percent_of_prediction	percent_of_DWPC	metapath
Alitretinoin—ABCB1—Mitomycin—urinary bladder cancer	0.102	0.401	CbGbCtD
Alitretinoin—ABCB1—Gemcitabine—urinary bladder cancer	0.0295	0.115	CbGbCtD
Alitretinoin—CYP1A2—Fluorouracil—urinary bladder cancer	0.0288	0.113	CbGbCtD
Alitretinoin—CYP1A2—Etoposide—urinary bladder cancer	0.0241	0.0942	CbGbCtD
Alitretinoin—ABCB1—Cisplatin—urinary bladder cancer	0.0214	0.0838	CbGbCtD
Alitretinoin—ABCB1—Etoposide—urinary bladder cancer	0.021	0.0824	CbGbCtD
Alitretinoin—ABCB1—Doxorubicin—urinary bladder cancer	0.0144	0.0562	CbGbCtD
Alitretinoin—ABCB1—Methotrexate—urinary bladder cancer	0.0139	0.0544	CbGbCtD
Alitretinoin—CRABP1—prostate gland—urinary bladder cancer	0.00872	0.0636	CbGeAlD
Alitretinoin—CRABP2—prostate gland—urinary bladder cancer	0.00789	0.0575	CbGeAlD
Alitretinoin—RARB—prostate gland—urinary bladder cancer	0.00705	0.0514	CbGeAlD
Alitretinoin—RXRG—prostate gland—urinary bladder cancer	0.0069	0.0502	CbGeAlD
Alitretinoin—CRABP2—seminal vesicle—urinary bladder cancer	0.00667	0.0486	CbGeAlD
Alitretinoin—CRABP1—urethra—urinary bladder cancer	0.00584	0.0426	CbGeAlD
Alitretinoin—RARG—prostate gland—urinary bladder cancer	0.00575	0.0419	CbGeAlD
Alitretinoin—CYP1A2—urine—urinary bladder cancer	0.00559	0.0407	CbGeAlD
Alitretinoin—CRABP2—smooth muscle tissue—urinary bladder cancer	0.00559	0.0407	CbGeAlD
Alitretinoin—RARA—prostate gland—urinary bladder cancer	0.00541	0.0394	CbGeAlD
Alitretinoin—RXRA—renal system—urinary bladder cancer	0.00535	0.039	CbGeAlD
Alitretinoin—CRABP2—urethra—urinary bladder cancer	0.00528	0.0385	CbGeAlD
Alitretinoin—CRABP1—female reproductive system—urinary bladder cancer	0.00476	0.0347	CbGeAlD
Alitretinoin—CRABP1—vagina—urinary bladder cancer	0.00431	0.0314	CbGeAlD
Alitretinoin—CRABP2—female reproductive system—urinary bladder cancer	0.00431	0.0314	CbGeAlD
Alitretinoin—RXRA—female reproductive system—urinary bladder cancer	0.00429	0.0312	CbGeAlD
Alitretinoin—CRABP2—vagina—urinary bladder cancer	0.00389	0.0284	CbGeAlD
Alitretinoin—RARG—urethra—urinary bladder cancer	0.00385	0.0281	CbGeAlD
Alitretinoin—RARB—female reproductive system—urinary bladder cancer	0.00385	0.0281	CbGeAlD
Alitretinoin—RARA—renal system—urinary bladder cancer	0.00369	0.0269	CbGeAlD
Alitretinoin—RARB—vagina—urinary bladder cancer	0.00348	0.0254	CbGeAlD
Alitretinoin—RXRB—vagina—urinary bladder cancer	0.0032	0.0233	CbGeAlD
Alitretinoin—RARG—female reproductive system—urinary bladder cancer	0.00314	0.0229	CbGeAlD
Alitretinoin—RARA—female reproductive system—urinary bladder cancer	0.00295	0.0215	CbGeAlD
Alitretinoin—RARG—vagina—urinary bladder cancer	0.00284	0.0207	CbGeAlD
Alitretinoin—RARB—lymph node—urinary bladder cancer	0.00225	0.0164	CbGeAlD
Alitretinoin—RARG—lymph node—urinary bladder cancer	0.00184	0.0134	CbGeAlD
Alitretinoin—RARA—lymph node—urinary bladder cancer	0.00173	0.0126	CbGeAlD
Alitretinoin—CYP1A2—renal system—urinary bladder cancer	0.00137	0.00996	CbGeAlD
Alitretinoin—ABCB1—prostate gland—urinary bladder cancer	0.00103	0.00749	CbGeAlD
Alitretinoin—ABCB1—seminal vesicle—urinary bladder cancer	0.000869	0.00633	CbGeAlD
Alitretinoin—ABCB1—epithelium—urinary bladder cancer	0.000755	0.0055	CbGeAlD
Alitretinoin—ABCB1—renal system—urinary bladder cancer	0.000701	0.0051	CbGeAlD
Alitretinoin—ABCB1—urethra—urinary bladder cancer	0.000688	0.00501	CbGeAlD
Alitretinoin—ABCB1—female reproductive system—urinary bladder cancer	0.000561	0.00409	CbGeAlD
Alitretinoin—ABCB1—vagina—urinary bladder cancer	0.000507	0.0037	CbGeAlD
Alitretinoin—ABCB1—lymph node—urinary bladder cancer	0.000328	0.00239	CbGeAlD
Alitretinoin—ABCB1—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	0.000126	0.000612	CbGpPWpGaD
Alitretinoin—RXRA—Generic Transcription Pathway—ESR2—urinary bladder cancer	0.000126	0.000612	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000126	0.000611	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—ESR2—urinary bladder cancer	0.000124	0.000601	CbGpPWpGaD
Alitretinoin—Body temperature increased—Etoposide—urinary bladder cancer	0.000124	0.000309	CcSEcCtD
Alitretinoin—Abdominal pain—Etoposide—urinary bladder cancer	0.000124	0.000309	CcSEcCtD
Alitretinoin—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000124	0.000309	CcSEcCtD
Alitretinoin—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000124	0.000309	CcSEcCtD
Alitretinoin—Haemorrhage—Epirubicin—urinary bladder cancer	0.000124	0.000308	CcSEcCtD
Alitretinoin—Hepatitis—Epirubicin—urinary bladder cancer	0.000124	0.000308	CcSEcCtD
Alitretinoin—Eye disorder—Methotrexate—urinary bladder cancer	0.000124	0.000308	CcSEcCtD
Alitretinoin—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000124	0.000308	CcSEcCtD
Alitretinoin—RXRA—Metabolism—UGT2B7—urinary bladder cancer	0.000123	0.000597	CbGpPWpGaD
Alitretinoin—Tinnitus—Methotrexate—urinary bladder cancer	0.000123	0.000307	CcSEcCtD
Alitretinoin—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000123	0.000307	CcSEcCtD
Alitretinoin—Asthenia—Cisplatin—urinary bladder cancer	0.000123	0.000306	CcSEcCtD
Alitretinoin—Pharyngitis—Epirubicin—urinary bladder cancer	0.000123	0.000306	CcSEcCtD
Alitretinoin—Sweating—Doxorubicin—urinary bladder cancer	0.000122	0.000305	CcSEcCtD
Alitretinoin—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000122	0.000305	CcSEcCtD
Alitretinoin—CRABP2—Metabolism—TYMS—urinary bladder cancer	0.000122	0.000591	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—TYMS—urinary bladder cancer	0.000122	0.000591	CbGpPWpGaD
Alitretinoin—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000122	0.000304	CcSEcCtD
Alitretinoin—RARB—Gene Expression—ESR2—urinary bladder cancer	0.000122	0.000589	CbGpPWpGaD
Alitretinoin—Haematuria—Doxorubicin—urinary bladder cancer	0.000122	0.000303	CcSEcCtD
Alitretinoin—Urethral disorder—Epirubicin—urinary bladder cancer	0.000121	0.000302	CcSEcCtD
Alitretinoin—CRABP2—Metabolism—GSTM1—urinary bladder cancer	0.00012	0.000584	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—NCOR1—urinary bladder cancer	0.00012	0.000584	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—GSTM1—urinary bladder cancer	0.00012	0.000584	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—NCOR1—urinary bladder cancer	0.00012	0.000584	CbGpPWpGaD
Alitretinoin—Epistaxis—Doxorubicin—urinary bladder cancer	0.00012	0.0003	CcSEcCtD
Alitretinoin—Angiopathy—Methotrexate—urinary bladder cancer	0.00012	0.000299	CcSEcCtD
Alitretinoin—Sinusitis—Doxorubicin—urinary bladder cancer	0.00012	0.000298	CcSEcCtD
Alitretinoin—Dizziness—Fluorouracil—urinary bladder cancer	0.000119	0.000298	CcSEcCtD
Alitretinoin—Visual impairment—Epirubicin—urinary bladder cancer	0.000119	0.000297	CcSEcCtD
Alitretinoin—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000119	0.000297	CcSEcCtD
Alitretinoin—Chills—Methotrexate—urinary bladder cancer	0.000119	0.000296	CcSEcCtD
Alitretinoin—Diarrhoea—Cisplatin—urinary bladder cancer	0.000117	0.000292	CcSEcCtD
Alitretinoin—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000117	0.000292	CcSEcCtD
Alitretinoin—Alopecia—Methotrexate—urinary bladder cancer	0.000117	0.000291	CcSEcCtD
Alitretinoin—Vomiting—Gemcitabine—urinary bladder cancer	0.000117	0.000291	CcSEcCtD
Alitretinoin—RARA—Gene Expression—ESR2—urinary bladder cancer	0.000117	0.000565	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—ESR2—urinary bladder cancer	0.000117	0.000565	CbGpPWpGaD
Alitretinoin—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	0.000116	0.000564	CbGpPWpGaD
Alitretinoin—Mental disorder—Methotrexate—urinary bladder cancer	0.000116	0.000289	CcSEcCtD
Alitretinoin—Rash—Gemcitabine—urinary bladder cancer	0.000116	0.000289	CcSEcCtD
Alitretinoin—Dermatitis—Gemcitabine—urinary bladder cancer	0.000116	0.000288	CcSEcCtD
Alitretinoin—Eye disorder—Epirubicin—urinary bladder cancer	0.000116	0.000288	CcSEcCtD
Alitretinoin—Hypersensitivity—Etoposide—urinary bladder cancer	0.000116	0.000288	CcSEcCtD
Alitretinoin—CRABP2—Metabolism—GPX1—urinary bladder cancer	0.000115	0.000559	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—GPX1—urinary bladder cancer	0.000115	0.000559	CbGpPWpGaD
Alitretinoin—Tinnitus—Epirubicin—urinary bladder cancer	0.000115	0.000288	CcSEcCtD
Alitretinoin—Malnutrition—Methotrexate—urinary bladder cancer	0.000115	0.000287	CcSEcCtD
Alitretinoin—Erythema—Methotrexate—urinary bladder cancer	0.000115	0.000287	CcSEcCtD
Alitretinoin—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000115	0.000287	CcSEcCtD
Alitretinoin—Headache—Gemcitabine—urinary bladder cancer	0.000115	0.000287	CcSEcCtD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000115	0.000557	CbGpPWpGaD
Alitretinoin—Flushing—Epirubicin—urinary bladder cancer	0.000115	0.000286	CcSEcCtD
Alitretinoin—Vomiting—Fluorouracil—urinary bladder cancer	0.000115	0.000286	CcSEcCtD
Alitretinoin—RXRA—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000115	0.000555	CbGpPWpGaD
Alitretinoin—Hepatitis—Doxorubicin—urinary bladder cancer	0.000114	0.000285	CcSEcCtD
Alitretinoin—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000114	0.000285	CcSEcCtD
Alitretinoin—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000114	0.000284	CcSEcCtD
Alitretinoin—Rash—Fluorouracil—urinary bladder cancer	0.000114	0.000284	CcSEcCtD
Alitretinoin—Dermatitis—Fluorouracil—urinary bladder cancer	0.000114	0.000284	CcSEcCtD
Alitretinoin—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000114	0.000283	CcSEcCtD
Alitretinoin—CRABP1—Metabolism—ERCC2—urinary bladder cancer	0.000113	0.000549	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—ERCC2—urinary bladder cancer	0.000113	0.000549	CbGpPWpGaD
Alitretinoin—Headache—Fluorouracil—urinary bladder cancer	0.000113	0.000282	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	0.000113	0.000548	CbGpPWpGaD
Alitretinoin—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000113	0.000282	CcSEcCtD
Alitretinoin—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000113	0.000281	CcSEcCtD
Alitretinoin—Asthenia—Etoposide—urinary bladder cancer	0.000112	0.000281	CcSEcCtD
Alitretinoin—Angiopathy—Epirubicin—urinary bladder cancer	0.000112	0.00028	CcSEcCtD
Alitretinoin—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000112	0.00028	CcSEcCtD
Alitretinoin—Back pain—Methotrexate—urinary bladder cancer	0.000111	0.000278	CcSEcCtD
Alitretinoin—Chills—Epirubicin—urinary bladder cancer	0.000111	0.000277	CcSEcCtD
Alitretinoin—RXRA—Metabolism—CYP4B1—urinary bladder cancer	0.000111	0.000538	CbGpPWpGaD
Alitretinoin—Pruritus—Etoposide—urinary bladder cancer	0.000111	0.000277	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	0.000111	0.000536	CbGpPWpGaD
Alitretinoin—Arrhythmia—Epirubicin—urinary bladder cancer	0.000111	0.000276	CcSEcCtD
Alitretinoin—Visual impairment—Doxorubicin—urinary bladder cancer	0.00011	0.000275	CcSEcCtD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	0.00011	0.000534	CbGpPWpGaD
Alitretinoin—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	0.00011	0.000534	CbGpPWpGaD
Alitretinoin—Alopecia—Epirubicin—urinary bladder cancer	0.000109	0.000273	CcSEcCtD
Alitretinoin—Nausea—Gemcitabine—urinary bladder cancer	0.000109	0.000272	CcSEcCtD
Alitretinoin—Vomiting—Cisplatin—urinary bladder cancer	0.000109	0.000271	CcSEcCtD
Alitretinoin—Vision blurred—Methotrexate—urinary bladder cancer	0.000108	0.00027	CcSEcCtD
Alitretinoin—Mental disorder—Epirubicin—urinary bladder cancer	0.000108	0.00027	CcSEcCtD
Alitretinoin—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000108	0.00027	CcSEcCtD
Alitretinoin—Rash—Cisplatin—urinary bladder cancer	0.000108	0.000269	CcSEcCtD
Alitretinoin—Dermatitis—Cisplatin—urinary bladder cancer	0.000108	0.000269	CcSEcCtD
Alitretinoin—Erythema—Epirubicin—urinary bladder cancer	0.000108	0.000269	CcSEcCtD
Alitretinoin—Malnutrition—Epirubicin—urinary bladder cancer	0.000108	0.000269	CcSEcCtD
Alitretinoin—Diarrhoea—Etoposide—urinary bladder cancer	0.000107	0.000268	CcSEcCtD
Alitretinoin—Nausea—Fluorouracil—urinary bladder cancer	0.000107	0.000267	CcSEcCtD
Alitretinoin—Eye disorder—Doxorubicin—urinary bladder cancer	0.000107	0.000267	CcSEcCtD
Alitretinoin—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	0.000107	0.000518	CbGpPWpGaD
Alitretinoin—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000107	0.000266	CcSEcCtD
Alitretinoin—Tinnitus—Doxorubicin—urinary bladder cancer	0.000107	0.000266	CcSEcCtD
Alitretinoin—CRABP2—Metabolism—MTHFR—urinary bladder cancer	0.000106	0.000516	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—MTHFR—urinary bladder cancer	0.000106	0.000516	CbGpPWpGaD
Alitretinoin—Anaemia—Methotrexate—urinary bladder cancer	0.000106	0.000265	CcSEcCtD
Alitretinoin—Flushing—Doxorubicin—urinary bladder cancer	0.000106	0.000265	CcSEcCtD
Alitretinoin—Flatulence—Epirubicin—urinary bladder cancer	0.000106	0.000265	CcSEcCtD
Alitretinoin—Tension—Epirubicin—urinary bladder cancer	0.000106	0.000264	CcSEcCtD
Alitretinoin—RXRA—Metabolism—SLC19A1—urinary bladder cancer	0.000105	0.000508	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—NCOR1—urinary bladder cancer	0.000105	0.000507	CbGpPWpGaD
Alitretinoin—Nervousness—Epirubicin—urinary bladder cancer	0.000105	0.000261	CcSEcCtD
Alitretinoin—Back pain—Epirubicin—urinary bladder cancer	0.000104	0.00026	CcSEcCtD
Alitretinoin—Angiopathy—Doxorubicin—urinary bladder cancer	0.000104	0.000259	CcSEcCtD
Alitretinoin—Malaise—Methotrexate—urinary bladder cancer	0.000104	0.000259	CcSEcCtD
Alitretinoin—Dizziness—Etoposide—urinary bladder cancer	0.000104	0.000259	CcSEcCtD
Alitretinoin—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000103	0.0005	CbGpPWpGaD
Alitretinoin—Chills—Doxorubicin—urinary bladder cancer	0.000103	0.000256	CcSEcCtD
Alitretinoin—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000102	0.000255	CcSEcCtD
Alitretinoin—RXRA—Metabolism—PRSS3—urinary bladder cancer	0.000102	0.000495	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.000102	0.000495	CbGpPWpGaD
Alitretinoin—Nausea—Cisplatin—urinary bladder cancer	0.000102	0.000253	CcSEcCtD
Alitretinoin—RXRA—Adipogenesis—TNF—urinary bladder cancer	0.000102	0.000492	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000102	0.000492	CbGpPWpGaD
Alitretinoin—Vision blurred—Epirubicin—urinary bladder cancer	0.000101	0.000253	CcSEcCtD
Alitretinoin—Alopecia—Doxorubicin—urinary bladder cancer	0.000101	0.000252	CcSEcCtD
Alitretinoin—Cough—Methotrexate—urinary bladder cancer	0.0001	0.00025	CcSEcCtD
Alitretinoin—Mental disorder—Doxorubicin—urinary bladder cancer	0.0001	0.00025	CcSEcCtD
Alitretinoin—Ill-defined disorder—Epirubicin—urinary bladder cancer	9.99e-05	0.000249	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	9.99e-05	0.000484	CbGpPWpGaD
Alitretinoin—Convulsion—Methotrexate—urinary bladder cancer	9.97e-05	0.000249	CcSEcCtD
Alitretinoin—Vomiting—Etoposide—urinary bladder cancer	9.97e-05	0.000249	CcSEcCtD
Alitretinoin—Malnutrition—Doxorubicin—urinary bladder cancer	9.96e-05	0.000248	CcSEcCtD
Alitretinoin—Erythema—Doxorubicin—urinary bladder cancer	9.96e-05	0.000248	CcSEcCtD
Alitretinoin—Anaemia—Epirubicin—urinary bladder cancer	9.95e-05	0.000248	CcSEcCtD
Alitretinoin—Agitation—Epirubicin—urinary bladder cancer	9.9e-05	0.000247	CcSEcCtD
Alitretinoin—Rash—Etoposide—urinary bladder cancer	9.89e-05	0.000247	CcSEcCtD
Alitretinoin—Dermatitis—Etoposide—urinary bladder cancer	9.88e-05	0.000246	CcSEcCtD
Alitretinoin—RARG—Gene Expression—ERCC2—urinary bladder cancer	9.84e-05	0.000477	CbGpPWpGaD
Alitretinoin—Headache—Etoposide—urinary bladder cancer	9.82e-05	0.000245	CcSEcCtD
Alitretinoin—Flatulence—Doxorubicin—urinary bladder cancer	9.82e-05	0.000245	CcSEcCtD
Alitretinoin—Arthralgia—Methotrexate—urinary bladder cancer	9.8e-05	0.000244	CcSEcCtD
Alitretinoin—Myalgia—Methotrexate—urinary bladder cancer	9.8e-05	0.000244	CcSEcCtD
Alitretinoin—Chest pain—Methotrexate—urinary bladder cancer	9.8e-05	0.000244	CcSEcCtD
Alitretinoin—Tension—Doxorubicin—urinary bladder cancer	9.78e-05	0.000244	CcSEcCtD
Alitretinoin—RXRA—Generic Transcription Pathway—NCOR1—urinary bladder cancer	9.74e-05	0.000472	CbGpPWpGaD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	9.73e-05	0.000243	CcSEcCtD
Alitretinoin—Malaise—Epirubicin—urinary bladder cancer	9.71e-05	0.000242	CcSEcCtD
Alitretinoin—Discomfort—Methotrexate—urinary bladder cancer	9.68e-05	0.000241	CcSEcCtD
Alitretinoin—Nervousness—Doxorubicin—urinary bladder cancer	9.68e-05	0.000241	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	9.66e-05	0.000468	CbGpPWpGaD
Alitretinoin—Syncope—Epirubicin—urinary bladder cancer	9.66e-05	0.000241	CcSEcCtD
Alitretinoin—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	9.64e-05	0.000467	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	9.64e-05	0.000467	CbGpPWpGaD
Alitretinoin—Back pain—Doxorubicin—urinary bladder cancer	9.64e-05	0.00024	CcSEcCtD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	9.63e-05	0.000467	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—NCOR1—urinary bladder cancer	9.57e-05	0.000464	CbGpPWpGaD
Alitretinoin—Palpitations—Epirubicin—urinary bladder cancer	9.52e-05	0.000237	CcSEcCtD
Alitretinoin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	9.51e-05	0.000461	CbGpPWpGaD
Alitretinoin—Confusional state—Methotrexate—urinary bladder cancer	9.47e-05	0.000236	CcSEcCtD
Alitretinoin—Loss of consciousness—Epirubicin—urinary bladder cancer	9.46e-05	0.000236	CcSEcCtD
Alitretinoin—Cough—Epirubicin—urinary bladder cancer	9.4e-05	0.000234	CcSEcCtD
Alitretinoin—Anaphylactic shock—Methotrexate—urinary bladder cancer	9.39e-05	0.000234	CcSEcCtD
Alitretinoin—Vision blurred—Doxorubicin—urinary bladder cancer	9.39e-05	0.000234	CcSEcCtD
Alitretinoin—RARB—Gene Expression—NCOR1—urinary bladder cancer	9.39e-05	0.000455	CbGpPWpGaD
Alitretinoin—Convulsion—Epirubicin—urinary bladder cancer	9.33e-05	0.000233	CcSEcCtD
Alitretinoin—Infection—Methotrexate—urinary bladder cancer	9.33e-05	0.000233	CcSEcCtD
Alitretinoin—Nausea—Etoposide—urinary bladder cancer	9.31e-05	0.000232	CcSEcCtD
Alitretinoin—Hypertension—Epirubicin—urinary bladder cancer	9.3e-05	0.000232	CcSEcCtD
Alitretinoin—Ill-defined disorder—Doxorubicin—urinary bladder cancer	9.24e-05	0.000231	CcSEcCtD
Alitretinoin—Nervous system disorder—Methotrexate—urinary bladder cancer	9.21e-05	0.00023	CcSEcCtD
Alitretinoin—Anaemia—Doxorubicin—urinary bladder cancer	9.21e-05	0.00023	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	9.2e-05	0.000446	CbGpPWpGaD
Alitretinoin—Thrombocytopenia—Methotrexate—urinary bladder cancer	9.19e-05	0.000229	CcSEcCtD
Alitretinoin—RXRA—Developmental Biology—NCOR1—urinary bladder cancer	9.17e-05	0.000444	CbGpPWpGaD
Alitretinoin—Arthralgia—Epirubicin—urinary bladder cancer	9.17e-05	0.000229	CcSEcCtD
Alitretinoin—Myalgia—Epirubicin—urinary bladder cancer	9.17e-05	0.000229	CcSEcCtD
Alitretinoin—Chest pain—Epirubicin—urinary bladder cancer	9.17e-05	0.000229	CcSEcCtD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	9.16e-05	0.000444	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	9.16e-05	0.000444	CbGpPWpGaD
Alitretinoin—Agitation—Doxorubicin—urinary bladder cancer	9.16e-05	0.000228	CcSEcCtD
Alitretinoin—Anxiety—Epirubicin—urinary bladder cancer	9.14e-05	0.000228	CcSEcCtD
Alitretinoin—Skin disorder—Methotrexate—urinary bladder cancer	9.12e-05	0.000227	CcSEcCtD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	9.1e-05	0.000227	CcSEcCtD
Alitretinoin—Hyperhidrosis—Methotrexate—urinary bladder cancer	9.08e-05	0.000226	CcSEcCtD
Alitretinoin—Discomfort—Epirubicin—urinary bladder cancer	9.06e-05	0.000226	CcSEcCtD
Alitretinoin—RXRG—Gene Expression—ERCC2—urinary bladder cancer	9e-05	0.000436	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—NCOR1—urinary bladder cancer	9e-05	0.000436	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—NCOR1—urinary bladder cancer	9e-05	0.000436	CbGpPWpGaD
Alitretinoin—Malaise—Doxorubicin—urinary bladder cancer	8.99e-05	0.000224	CcSEcCtD
Alitretinoin—Dry mouth—Epirubicin—urinary bladder cancer	8.97e-05	0.000224	CcSEcCtD
Alitretinoin—Anorexia—Methotrexate—urinary bladder cancer	8.95e-05	0.000223	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	8.94e-05	0.000433	CbGpPWpGaD
Alitretinoin—Syncope—Doxorubicin—urinary bladder cancer	8.94e-05	0.000223	CcSEcCtD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	8.91e-05	0.000432	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	8.91e-05	0.000432	CbGpPWpGaD
Alitretinoin—RARG—Generic Transcription Pathway—MYC—urinary bladder cancer	8.88e-05	0.000431	CbGpPWpGaD
Alitretinoin—Confusional state—Epirubicin—urinary bladder cancer	8.86e-05	0.000221	CcSEcCtD
Alitretinoin—RARB—Gene Expression—ERCC2—urinary bladder cancer	8.83e-05	0.000428	CbGpPWpGaD
Alitretinoin—Palpitations—Doxorubicin—urinary bladder cancer	8.81e-05	0.00022	CcSEcCtD
Alitretinoin—Anaphylactic shock—Epirubicin—urinary bladder cancer	8.79e-05	0.000219	CcSEcCtD
Alitretinoin—Oedema—Epirubicin—urinary bladder cancer	8.79e-05	0.000219	CcSEcCtD
Alitretinoin—Hypotension—Methotrexate—urinary bladder cancer	8.78e-05	0.000219	CcSEcCtD
Alitretinoin—Loss of consciousness—Doxorubicin—urinary bladder cancer	8.76e-05	0.000218	CcSEcCtD
Alitretinoin—Infection—Epirubicin—urinary bladder cancer	8.73e-05	0.000218	CcSEcCtD
Alitretinoin—Cough—Doxorubicin—urinary bladder cancer	8.69e-05	0.000217	CcSEcCtD
Alitretinoin—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	8.68e-05	0.000421	CbGpPWpGaD
Alitretinoin—Shock—Epirubicin—urinary bladder cancer	8.65e-05	0.000216	CcSEcCtD
Alitretinoin—CRABP2—Metabolism—PPARG—urinary bladder cancer	8.63e-05	0.000419	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—PPARG—urinary bladder cancer	8.63e-05	0.000419	CbGpPWpGaD
Alitretinoin—Convulsion—Doxorubicin—urinary bladder cancer	8.63e-05	0.000215	CcSEcCtD
Alitretinoin—Nervous system disorder—Epirubicin—urinary bladder cancer	8.62e-05	0.000215	CcSEcCtD
Alitretinoin—Thrombocytopenia—Epirubicin—urinary bladder cancer	8.6e-05	0.000215	CcSEcCtD
Alitretinoin—Hypertension—Doxorubicin—urinary bladder cancer	8.6e-05	0.000215	CcSEcCtD
Alitretinoin—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	8.6e-05	0.000417	CbGpPWpGaD
Alitretinoin—Tachycardia—Epirubicin—urinary bladder cancer	8.58e-05	0.000214	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	8.56e-05	0.000213	CcSEcCtD
Alitretinoin—Skin disorder—Epirubicin—urinary bladder cancer	8.54e-05	0.000213	CcSEcCtD
Alitretinoin—Hyperhidrosis—Epirubicin—urinary bladder cancer	8.5e-05	0.000212	CcSEcCtD
Alitretinoin—Insomnia—Methotrexate—urinary bladder cancer	8.49e-05	0.000212	CcSEcCtD
Alitretinoin—Arthralgia—Doxorubicin—urinary bladder cancer	8.48e-05	0.000212	CcSEcCtD
Alitretinoin—Chest pain—Doxorubicin—urinary bladder cancer	8.48e-05	0.000212	CcSEcCtD
Alitretinoin—Myalgia—Doxorubicin—urinary bladder cancer	8.48e-05	0.000212	CcSEcCtD
Alitretinoin—RARA—Gene Expression—ERCC2—urinary bladder cancer	8.46e-05	0.00041	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—ERCC2—urinary bladder cancer	8.46e-05	0.00041	CbGpPWpGaD
Alitretinoin—Anxiety—Doxorubicin—urinary bladder cancer	8.45e-05	0.000211	CcSEcCtD
Alitretinoin—Paraesthesia—Methotrexate—urinary bladder cancer	8.43e-05	0.00021	CcSEcCtD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	8.42e-05	0.00021	CcSEcCtD
Alitretinoin—Discomfort—Doxorubicin—urinary bladder cancer	8.38e-05	0.000209	CcSEcCtD
Alitretinoin—Anorexia—Epirubicin—urinary bladder cancer	8.38e-05	0.000209	CcSEcCtD
Alitretinoin—Dyspnoea—Methotrexate—urinary bladder cancer	8.37e-05	0.000209	CcSEcCtD
Alitretinoin—Somnolence—Methotrexate—urinary bladder cancer	8.35e-05	0.000208	CcSEcCtD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	8.31e-05	0.000403	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	8.3e-05	0.000402	CbGpPWpGaD
Alitretinoin—Dry mouth—Doxorubicin—urinary bladder cancer	8.3e-05	0.000207	CcSEcCtD
Alitretinoin—CRABP1—Metabolism—CREBBP—urinary bladder cancer	8.29e-05	0.000402	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—CREBBP—urinary bladder cancer	8.29e-05	0.000402	CbGpPWpGaD
Alitretinoin—Dyspepsia—Methotrexate—urinary bladder cancer	8.27e-05	0.000206	CcSEcCtD
Alitretinoin—RARG—Gene Expression—ESR1—urinary bladder cancer	8.22e-05	0.000398	CbGpPWpGaD
Alitretinoin—Hypotension—Epirubicin—urinary bladder cancer	8.21e-05	0.000205	CcSEcCtD
Alitretinoin—Confusional state—Doxorubicin—urinary bladder cancer	8.2e-05	0.000204	CcSEcCtD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	8.19e-05	0.000397	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—TYMP—urinary bladder cancer	8.17e-05	0.000396	CbGpPWpGaD
Alitretinoin—Decreased appetite—Methotrexate—urinary bladder cancer	8.16e-05	0.000204	CcSEcCtD
Alitretinoin—Anaphylactic shock—Doxorubicin—urinary bladder cancer	8.13e-05	0.000203	CcSEcCtD
Alitretinoin—Oedema—Doxorubicin—urinary bladder cancer	8.13e-05	0.000203	CcSEcCtD
Alitretinoin—RXRG—Generic Transcription Pathway—MYC—urinary bladder cancer	8.12e-05	0.000394	CbGpPWpGaD
Alitretinoin—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	8.11e-05	0.000202	CcSEcCtD
Alitretinoin—Fatigue—Methotrexate—urinary bladder cancer	8.1e-05	0.000202	CcSEcCtD
Alitretinoin—Infection—Doxorubicin—urinary bladder cancer	8.08e-05	0.000201	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	8.07e-05	0.000391	CbGpPWpGaD
Alitretinoin—Pain—Methotrexate—urinary bladder cancer	8.03e-05	0.0002	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	8.01e-05	0.000388	CbGpPWpGaD
Alitretinoin—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	8.01e-05	0.0002	CcSEcCtD
Alitretinoin—Shock—Doxorubicin—urinary bladder cancer	8e-05	0.0002	CcSEcCtD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	7.98e-05	0.000387	CbGpPWpGaD
Alitretinoin—Nervous system disorder—Doxorubicin—urinary bladder cancer	7.97e-05	0.000199	CcSEcCtD
Alitretinoin—RARB—Generic Transcription Pathway—MYC—urinary bladder cancer	7.97e-05	0.000386	CbGpPWpGaD
Alitretinoin—Thrombocytopenia—Doxorubicin—urinary bladder cancer	7.96e-05	0.000199	CcSEcCtD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	7.95e-05	0.000385	CbGpPWpGaD
Alitretinoin—Insomnia—Epirubicin—urinary bladder cancer	7.95e-05	0.000198	CcSEcCtD
Alitretinoin—Tachycardia—Doxorubicin—urinary bladder cancer	7.94e-05	0.000198	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	7.93e-05	0.000384	CbGpPWpGaD
Alitretinoin—Skin disorder—Doxorubicin—urinary bladder cancer	7.9e-05	0.000197	CcSEcCtD
Alitretinoin—Paraesthesia—Epirubicin—urinary bladder cancer	7.89e-05	0.000197	CcSEcCtD
Alitretinoin—Hyperhidrosis—Doxorubicin—urinary bladder cancer	7.86e-05	0.000196	CcSEcCtD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	7.84e-05	0.00038	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	7.84e-05	0.00038	CbGpPWpGaD
Alitretinoin—Dyspnoea—Epirubicin—urinary bladder cancer	7.84e-05	0.000195	CcSEcCtD
Alitretinoin—Somnolence—Epirubicin—urinary bladder cancer	7.81e-05	0.000195	CcSEcCtD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	7.81e-05	0.000379	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	7.81e-05	0.000379	CbGpPWpGaD
Alitretinoin—Anorexia—Doxorubicin—urinary bladder cancer	7.75e-05	0.000193	CcSEcCtD
Alitretinoin—Feeling abnormal—Methotrexate—urinary bladder cancer	7.74e-05	0.000193	CcSEcCtD
Alitretinoin—Dyspepsia—Epirubicin—urinary bladder cancer	7.74e-05	0.000193	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Methotrexate—urinary bladder cancer	7.68e-05	0.000191	CcSEcCtD
Alitretinoin—RXRA—Generic Transcription Pathway—ESR1—urinary bladder cancer	7.65e-05	0.000371	CbGpPWpGaD
Alitretinoin—Decreased appetite—Epirubicin—urinary bladder cancer	7.64e-05	0.000191	CcSEcCtD
Alitretinoin—RARA—Generic Transcription Pathway—MYC—urinary bladder cancer	7.64e-05	0.00037	CbGpPWpGaD
Alitretinoin—RXRB—Generic Transcription Pathway—MYC—urinary bladder cancer	7.64e-05	0.00037	CbGpPWpGaD
Alitretinoin—Hypotension—Doxorubicin—urinary bladder cancer	7.6e-05	0.000189	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	7.59e-05	0.000189	CcSEcCtD
Alitretinoin—Fatigue—Epirubicin—urinary bladder cancer	7.58e-05	0.000189	CcSEcCtD
Alitretinoin—RXRG—Gene Expression—ESR1—urinary bladder cancer	7.52e-05	0.000364	CbGpPWpGaD
Alitretinoin—Pain—Epirubicin—urinary bladder cancer	7.52e-05	0.000187	CcSEcCtD
Alitretinoin—Constipation—Epirubicin—urinary bladder cancer	7.52e-05	0.000187	CcSEcCtD
Alitretinoin—RARG—Gene Expression—PPARG—urinary bladder cancer	7.5e-05	0.000364	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	7.46e-05	0.000362	CbGpPWpGaD
Alitretinoin—Urticaria—Methotrexate—urinary bladder cancer	7.46e-05	0.000186	CcSEcCtD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	7.44e-05	0.000361	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	7.44e-05	0.000361	CbGpPWpGaD
Alitretinoin—Abdominal pain—Methotrexate—urinary bladder cancer	7.42e-05	0.000185	CcSEcCtD
Alitretinoin—Body temperature increased—Methotrexate—urinary bladder cancer	7.42e-05	0.000185	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	7.41e-05	0.000185	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	7.4e-05	0.000359	CbGpPWpGaD
Alitretinoin—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	7.4e-05	0.000359	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—NAT2—urinary bladder cancer	7.38e-05	0.000358	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	7.38e-05	0.000358	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—ESR1—urinary bladder cancer	7.37e-05	0.000357	CbGpPWpGaD
Alitretinoin—Insomnia—Doxorubicin—urinary bladder cancer	7.35e-05	0.000183	CcSEcCtD
Alitretinoin—Paraesthesia—Doxorubicin—urinary bladder cancer	7.3e-05	0.000182	CcSEcCtD
Alitretinoin—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	7.3e-05	0.000354	CbGpPWpGaD
Alitretinoin—Dyspnoea—Doxorubicin—urinary bladder cancer	7.25e-05	0.000181	CcSEcCtD
Alitretinoin—Feeling abnormal—Epirubicin—urinary bladder cancer	7.24e-05	0.000181	CcSEcCtD
Alitretinoin—RXRA—Developmental Biology—CDK4—urinary bladder cancer	7.23e-05	0.000351	CbGpPWpGaD
Alitretinoin—Somnolence—Doxorubicin—urinary bladder cancer	7.23e-05	0.00018	CcSEcCtD
Alitretinoin—RARG—Gene Expression—CREBBP—urinary bladder cancer	7.21e-05	0.000349	CbGpPWpGaD
Alitretinoin—Gastrointestinal pain—Epirubicin—urinary bladder cancer	7.19e-05	0.000179	CcSEcCtD
Alitretinoin—Dyspepsia—Doxorubicin—urinary bladder cancer	7.16e-05	0.000179	CcSEcCtD
Alitretinoin—RXRB—Gene Expression—ESR1—urinary bladder cancer	7.07e-05	0.000343	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—ESR1—urinary bladder cancer	7.07e-05	0.000343	CbGpPWpGaD
Alitretinoin—Decreased appetite—Doxorubicin—urinary bladder cancer	7.07e-05	0.000176	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	7.03e-05	0.000341	CbGpPWpGaD
Alitretinoin—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	7.02e-05	0.000175	CcSEcCtD
Alitretinoin—Fatigue—Doxorubicin—urinary bladder cancer	7.01e-05	0.000175	CcSEcCtD
Alitretinoin—Urticaria—Epirubicin—urinary bladder cancer	6.98e-05	0.000174	CcSEcCtD
Alitretinoin—RXRA—Generic Transcription Pathway—PPARG—urinary bladder cancer	6.98e-05	0.000338	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—SMC1A—urinary bladder cancer	6.97e-05	0.000338	CbGpPWpGaD
Alitretinoin—Pain—Doxorubicin—urinary bladder cancer	6.95e-05	0.000173	CcSEcCtD
Alitretinoin—Constipation—Doxorubicin—urinary bladder cancer	6.95e-05	0.000173	CcSEcCtD
Alitretinoin—Body temperature increased—Epirubicin—urinary bladder cancer	6.95e-05	0.000173	CcSEcCtD
Alitretinoin—Abdominal pain—Epirubicin—urinary bladder cancer	6.95e-05	0.000173	CcSEcCtD
Alitretinoin—Hypersensitivity—Methotrexate—urinary bladder cancer	6.92e-05	0.000173	CcSEcCtD
Alitretinoin—RXRG—Gene Expression—PPARG—urinary bladder cancer	6.86e-05	0.000333	CbGpPWpGaD
Alitretinoin—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	6.8e-05	0.00033	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—PTGS2—urinary bladder cancer	6.79e-05	0.000329	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—PTGS2—urinary bladder cancer	6.79e-05	0.000329	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	6.78e-05	0.000329	CbGpPWpGaD
Alitretinoin—Asthenia—Methotrexate—urinary bladder cancer	6.74e-05	0.000168	CcSEcCtD
Alitretinoin—RARB—Gene Expression—PPARG—urinary bladder cancer	6.73e-05	0.000326	CbGpPWpGaD
Alitretinoin—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	6.71e-05	0.000325	CbGpPWpGaD
Alitretinoin—RXRA—Generic Transcription Pathway—CREBBP—urinary bladder cancer	6.71e-05	0.000325	CbGpPWpGaD
Alitretinoin—Feeling abnormal—Doxorubicin—urinary bladder cancer	6.7e-05	0.000167	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	6.65e-05	0.000166	CcSEcCtD
Alitretinoin—Pruritus—Methotrexate—urinary bladder cancer	6.64e-05	0.000166	CcSEcCtD
Alitretinoin—RXRG—Gene Expression—CREBBP—urinary bladder cancer	6.59e-05	0.000319	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	6.58e-05	0.000319	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—PPARG—urinary bladder cancer	6.57e-05	0.000319	CbGpPWpGaD
Alitretinoin—Hypersensitivity—Epirubicin—urinary bladder cancer	6.48e-05	0.000161	CcSEcCtD
Alitretinoin—RARB—Gene Expression—CREBBP—urinary bladder cancer	6.46e-05	0.000313	CbGpPWpGaD
Alitretinoin—Urticaria—Doxorubicin—urinary bladder cancer	6.46e-05	0.000161	CcSEcCtD
Alitretinoin—RARA—Gene Expression—PPARG—urinary bladder cancer	6.45e-05	0.000313	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—PPARG—urinary bladder cancer	6.45e-05	0.000313	CbGpPWpGaD
Alitretinoin—Abdominal pain—Doxorubicin—urinary bladder cancer	6.43e-05	0.00016	CcSEcCtD
Alitretinoin—Body temperature increased—Doxorubicin—urinary bladder cancer	6.43e-05	0.00016	CcSEcCtD
Alitretinoin—Diarrhoea—Methotrexate—urinary bladder cancer	6.43e-05	0.00016	CcSEcCtD
Alitretinoin—RXRA—Metabolism—RRM2—urinary bladder cancer	6.37e-05	0.000309	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—CREBBP—urinary bladder cancer	6.31e-05	0.000306	CbGpPWpGaD
Alitretinoin—Asthenia—Epirubicin—urinary bladder cancer	6.31e-05	0.000157	CcSEcCtD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	6.27e-05	0.000304	CbGpPWpGaD
Alitretinoin—Pruritus—Epirubicin—urinary bladder cancer	6.22e-05	0.000155	CcSEcCtD
Alitretinoin—Dizziness—Methotrexate—urinary bladder cancer	6.21e-05	0.000155	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	6.21e-05	0.000301	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—CREBBP—urinary bladder cancer	6.2e-05	0.0003	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—CREBBP—urinary bladder cancer	6.2e-05	0.0003	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	6.18e-05	0.0003	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	6.16e-05	0.000298	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—ESR2—urinary bladder cancer	6.07e-05	0.000294	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	6.04e-05	0.000293	CbGpPWpGaD
Alitretinoin—Diarrhoea—Epirubicin—urinary bladder cancer	6.01e-05	0.00015	CcSEcCtD
Alitretinoin—Hypersensitivity—Doxorubicin—urinary bladder cancer	5.99e-05	0.000149	CcSEcCtD
Alitretinoin—Vomiting—Methotrexate—urinary bladder cancer	5.97e-05	0.000149	CcSEcCtD
Alitretinoin—CRABP2—Metabolism—PTEN—urinary bladder cancer	5.92e-05	0.000287	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—PTEN—urinary bladder cancer	5.92e-05	0.000287	CbGpPWpGaD
Alitretinoin—Rash—Methotrexate—urinary bladder cancer	5.92e-05	0.000148	CcSEcCtD
Alitretinoin—Dermatitis—Methotrexate—urinary bladder cancer	5.92e-05	0.000148	CcSEcCtD
Alitretinoin—RXRA—Metabolism—HPGDS—urinary bladder cancer	5.9e-05	0.000286	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—ENO2—urinary bladder cancer	5.9e-05	0.000286	CbGpPWpGaD
Alitretinoin—Headache—Methotrexate—urinary bladder cancer	5.88e-05	0.000147	CcSEcCtD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.87e-05	0.000284	CbGpPWpGaD
Alitretinoin—Asthenia—Doxorubicin—urinary bladder cancer	5.83e-05	0.000145	CcSEcCtD
Alitretinoin—Dizziness—Epirubicin—urinary bladder cancer	5.81e-05	0.000145	CcSEcCtD
Alitretinoin—Pruritus—Doxorubicin—urinary bladder cancer	5.75e-05	0.000143	CcSEcCtD
Alitretinoin—RXRA—Metabolism—GSTT1—urinary bladder cancer	5.73e-05	0.000278	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—RHOA—urinary bladder cancer	5.71e-05	0.000277	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	5.68e-05	0.000275	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—EP300—urinary bladder cancer	5.65e-05	0.000274	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—EP300—urinary bladder cancer	5.65e-05	0.000274	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.64e-05	0.000273	CbGpPWpGaD
Alitretinoin—Vomiting—Epirubicin—urinary bladder cancer	5.59e-05	0.000139	CcSEcCtD
Alitretinoin—Nausea—Methotrexate—urinary bladder cancer	5.58e-05	0.000139	CcSEcCtD
Alitretinoin—Diarrhoea—Doxorubicin—urinary bladder cancer	5.56e-05	0.000139	CcSEcCtD
Alitretinoin—Rash—Epirubicin—urinary bladder cancer	5.54e-05	0.000138	CcSEcCtD
Alitretinoin—Dermatitis—Epirubicin—urinary bladder cancer	5.54e-05	0.000138	CcSEcCtD
Alitretinoin—Headache—Epirubicin—urinary bladder cancer	5.51e-05	0.000137	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	5.4e-05	0.000262	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—GSTO2—urinary bladder cancer	5.39e-05	0.000261	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—NAT1—urinary bladder cancer	5.39e-05	0.000261	CbGpPWpGaD
Alitretinoin—Dizziness—Doxorubicin—urinary bladder cancer	5.38e-05	0.000134	CcSEcCtD
Alitretinoin—RXRA—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.36e-05	0.00026	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	5.33e-05	0.000258	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—ERBB2—urinary bladder cancer	5.29e-05	0.000256	CbGpPWpGaD
Alitretinoin—Nausea—Epirubicin—urinary bladder cancer	5.22e-05	0.00013	CcSEcCtD
Alitretinoin—Vomiting—Doxorubicin—urinary bladder cancer	5.17e-05	0.000129	CcSEcCtD
Alitretinoin—Rash—Doxorubicin—urinary bladder cancer	5.13e-05	0.000128	CcSEcCtD
Alitretinoin—Dermatitis—Doxorubicin—urinary bladder cancer	5.12e-05	0.000128	CcSEcCtD
Alitretinoin—Headache—Doxorubicin—urinary bladder cancer	5.09e-05	0.000127	CcSEcCtD
Alitretinoin—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	4.93e-05	0.000239	CbGpPWpGaD
Alitretinoin—Nausea—Doxorubicin—urinary bladder cancer	4.83e-05	0.00012	CcSEcCtD
Alitretinoin—RXRA—Metabolism—NQO1—urinary bladder cancer	4.76e-05	0.000231	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—NCOR1—urinary bladder cancer	4.69e-05	0.000227	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.62e-05	0.000224	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	4.58e-05	0.000222	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	4.54e-05	0.00022	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—MMP9—urinary bladder cancer	4.53e-05	0.00022	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	4.52e-05	0.000219	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	4.44e-05	0.000215	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	4.42e-05	0.000214	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—ERCC2—urinary bladder cancer	4.41e-05	0.000214	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	4.3e-05	0.000208	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—NAT1—urinary bladder cancer	4.3e-05	0.000208	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—EP300—urinary bladder cancer	4.3e-05	0.000208	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—MYC—urinary bladder cancer	4.28e-05	0.000207	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	4.23e-05	0.000205	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	4.19e-05	0.000203	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—SRC—urinary bladder cancer	4.18e-05	0.000203	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—PRSS3—urinary bladder cancer	4.08e-05	0.000198	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.03e-05	0.000195	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	3.99e-05	0.000194	CbGpPWpGaD
Alitretinoin—RXRA—Generic Transcription Pathway—MYC—urinary bladder cancer	3.98e-05	0.000193	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—GSTP1—urinary bladder cancer	3.97e-05	0.000192	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	3.93e-05	0.000191	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—MYC—urinary bladder cancer	3.91e-05	0.00019	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	3.86e-05	0.000187	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	3.85e-05	0.000187	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.84e-05	0.000186	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—MYC—urinary bladder cancer	3.84e-05	0.000186	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—TYMS—urinary bladder cancer	3.69e-05	0.000179	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—ESR1—urinary bladder cancer	3.68e-05	0.000179	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—MYC—urinary bladder cancer	3.68e-05	0.000178	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—MYC—urinary bladder cancer	3.68e-05	0.000178	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	3.67e-05	0.000178	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—EGFR—urinary bladder cancer	3.66e-05	0.000178	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—GSTM1—urinary bladder cancer	3.65e-05	0.000177	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—NCOR1—urinary bladder cancer	3.65e-05	0.000177	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	3.57e-05	0.000173	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	3.54e-05	0.000172	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—GPX1—urinary bladder cancer	3.49e-05	0.000169	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—TNF—urinary bladder cancer	3.49e-05	0.000169	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—KRAS—urinary bladder cancer	3.46e-05	0.000168	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—ERCC2—urinary bladder cancer	3.43e-05	0.000166	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—PPARG—urinary bladder cancer	3.36e-05	0.000163	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	3.34e-05	0.000162	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—TYMP—urinary bladder cancer	3.26e-05	0.000158	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	3.26e-05	0.000158	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—CREBBP—urinary bladder cancer	3.23e-05	0.000157	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—MTHFR—urinary bladder cancer	3.22e-05	0.000156	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.2e-05	0.000155	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.13e-05	0.000152	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.98e-05	0.000145	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.96e-05	0.000143	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—NAT2—urinary bladder cancer	2.95e-05	0.000143	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—HRAS—urinary bladder cancer	2.94e-05	0.000143	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.63e-05	0.000127	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—PPARG—urinary bladder cancer	2.61e-05	0.000127	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.61e-05	0.000127	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—TYMP—urinary bladder cancer	2.6e-05	0.000126	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—RRM2—urinary bladder cancer	2.55e-05	0.000123	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—CREBBP—urinary bladder cancer	2.51e-05	0.000122	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.5e-05	0.000121	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—HPGDS—urinary bladder cancer	2.36e-05	0.000114	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—ENO2—urinary bladder cancer	2.36e-05	0.000114	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—NAT2—urinary bladder cancer	2.36e-05	0.000114	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—GSTT1—urinary bladder cancer	2.29e-05	0.000111	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.14e-05	0.000104	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—PTGS2—urinary bladder cancer	2.06e-05	9.97e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—RRM2—urinary bladder cancer	2.03e-05	9.86e-05	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—MYC—urinary bladder cancer	1.92e-05	9.29e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.9e-05	9.22e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	1.88e-05	9.13e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—ENO2—urinary bladder cancer	1.88e-05	9.13e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.87e-05	9.08e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	1.83e-05	8.85e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.8e-05	8.72e-05	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—PTEN—urinary bladder cancer	1.79e-05	8.69e-05	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—EP300—urinary bladder cancer	1.71e-05	8.29e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.59e-05	7.69e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—NQO1—urinary bladder cancer	1.52e-05	7.36e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.47e-05	7.15e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.47e-05	7.14e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.46e-05	7.06e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.46e-05	7.06e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.4e-05	6.77e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.37e-05	6.64e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.29e-05	6.24e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.28e-05	6.23e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1.27e-05	6.14e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.22e-05	5.94e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—TYMS—urinary bladder cancer	1.18e-05	5.71e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.16e-05	5.64e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.16e-05	5.64e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.11e-05	5.4e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.09e-05	5.3e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.04e-05	5.06e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	1.03e-05	4.98e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1e-05	4.86e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—PPARG—urinary bladder cancer	8.34e-06	4.04e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—PTGS2—urinary bladder cancer	8.22e-06	3.98e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	8.01e-06	3.88e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—PTEN—urinary bladder cancer	7.17e-06	3.47e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—EP300—urinary bladder cancer	6.83e-06	3.31e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	6.56e-06	3.18e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—PTEN—urinary bladder cancer	5.72e-06	2.77e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—EP300—urinary bladder cancer	5.46e-06	2.64e-05	CbGpPWpGaD
